Drug-induced psychiatric disorders: A pharmacovigilance update

被引:2
作者
Montastruc, Francois [1 ,2 ,4 ,5 ]
de Laportaliere, Tanguy Taillefer [3 ]
机构
[1] Toulouse Univ Hosp CHU, Fac Med, Ctr PharmacoVigilance & Pharmacoepidemiol, Dept Med & Clin Pharmacol, F-31000 Toulouse, France
[2] Toulouse Univ Hosp, Team PEPSS Pharmacol Populat cohorteS & biobanqueS, CIC 1436, F-31000 Toulouse, France
[3] CHU, Toulouse Univ Hosp, Dept Pharm, F-31000 Toulouse, France
[4] Fac Med, Dept Clin & Med Pharmacol, 37 Allees Jules-Guesde, F-31000 Toulouse, France
[5] Toulouse Univ Hosp, 37 Allees Jules-Guesde, F-31000 Toulouse, France
来源
THERAPIE | 2024年 / 79卷 / 02期
关键词
Drug induced psychiatric disorders; Depression; Psychosis; Anxiety; Pharmacovigilance; DEPRESSION; ESKETAMINE; RISK; NIGHTMARES; PSYCHOSIS; EFFICACY; SUICIDE; ANXIETY;
D O I
10.1016/j.therap.2023.09.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The psychiatric risks associated with drugs are sometimes one of the few restrictions on the use of certain drug classes, such as corticosteroids in patients with a history of severe psychotic episodes associated with this drug class. In this non-exhaustive review, we propose to deal with the most recent issues concerning psychiatric disorders induced by drugs and encountered in doctors' clinical practice. Firstly, we look at depressive disorders and suicide risks, secondly at psychotic and manic disorders and thirdly at anxiety and sleep disorders. While lot of drugs are associated with psychiatric disorders, the confounding by indication represents an important methodological gap since information on the psychiatric profile of patients is not always available. This is particularly the case for serotonin reuptake inhibitors and esketamine used as antidepressants. Recent pharmacovigilance concerns of psychiatric disorders emerged with montelukast, orexin receptor antagonists or cystic fibrosis transmembrane regulator (CFTR) modulators. (c) 2023 Soci & eacute;t & eacute; franc , aise de pharmacologie et de th & eacute;rapeutique. Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:173 / 179
页数:7
相关论文
共 57 条
[1]  
American Psychiatric Association, 2013, Diagnostic and Statistical Manual of Mental Disorders, Vfifth, DOI 10.1176/appi.books.9780890425596
[2]   Drug-induced panic attacks: Analysis of cases registered in the French pharmacovigilance database [J].
Apadie, Delphine ;
Essilini, Abais ;
Fulda, Virginie ;
Gouraud, Aurore ;
Yelehe-Okouma, Melissa ;
Micallef, Joelle ;
Montastruc, Francois ;
Montastruc, Jean Louis .
JOURNAL OF PSYCHIATRIC RESEARCH, 2017, 90 :60-66
[3]   Management of neuropsychiatric symptoms in adults treated with elexacaftor/tezacaftor/ivacaftor [J].
Baroud, Evelyne ;
Chaudhary, Nivedita ;
Georgiopoulos, Anna M. .
PEDIATRIC PULMONOLOGY, 2023, 58 (07) :1920-1930
[4]  
Base de Donnees Publique des Medicaments, RESUME CARACTERISTIQ
[5]  
Bathgate C., 2021, J CYST FIBROS, V20, pS130, DOI [DOI 10.1016/S1569-1993(21)01695-7, 10.1016/S1569-1993(21)01695-7]
[6]  
Carton L, 2021, THERAPIE, V76, P137, DOI [10.1016/therap.2020.12.010, 10.1016/j.therap.2020.12.010]
[7]   Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy [J].
Chouinard, Guy ;
Samaha, Anne-Noel ;
Chouinard, Virginie-Anne ;
Peretti, Charles-Siegfried ;
Kanahara, Nobuhisa ;
Takase, Masayuki ;
Iyo, Masaomi .
PSYCHOTHERAPY AND PSYCHOSOMATICS, 2017, 86 (04) :189-219
[8]   US Food and Drug Administration approval of esketamine and brexanolone [J].
Cristea, Ioana A. ;
Naudet, Florian .
LANCET PSYCHIATRY, 2019, 6 (12) :975-977
[9]   Reporting of harms in clinical trials of esketamine in depression: a systematic review [J].
de Laportaliere, Tanguy Taillefer ;
Jullien, Adeline ;
Yrondi, Antoine ;
Cestac, Philippe ;
Montastruc, Francois .
PSYCHOLOGICAL MEDICINE, 2023, 53 (10) :4305-4315
[10]  
Dodds Tyler J, 2017, Prim Care Companion CNS Disord, V19, DOI 10.4088/PCC.16r02037